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On examination of the records of 1321 patients following
kidney transplant over an 11-year period, we found that
29 patients had recurrent membranoproliferative
glomerulonephritis (MPGN). We excluded from this analysis
patients who had MPGN type II, those with clear evidence of
secondary MPGN, and those lacking post-transplant biopsies.
During an average of 53 months of follow-up, we found
using protocol biopsies that 12 of these patients had
recurrent MPGN diagnosed 1 week to 14 months post-
transplant. In 4 of the 12 patients this presented clinically,
whereas the remaining had subclinical disease. The risk of
recurrence was significantly increased in patients with low
complement levels. Serum monoclonal proteins were found
in a total of six patients; appeared to be associated with
earlier, more aggressive disease; and were more common in
recurrent than non-recurrent disease. The recurrence of
MPGN was marginally higher in recipients of living-donor
kidneys. Some patients developed characteristic lesions
within 2 months post-transplant, whereas others presented
with minimal, atypical histological changes that progressed
to MPGN. Of 29 patients, 5 lost their allograft and 2 patients
remain on chronic plasmapheresis. Our study shows the risk
of MPGN recurrence and progression depends on identifiable
pretransplant characteristics, has variable clinical impact, and
can result in graft failure.
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Membranoproliferative glomerulonephritis (MPGN), or
mesangiocapillary glomerulonephritis, refers to a specific
histological pattern of glomerular injury that is characterized
by glomerular mesangial expansion due to both increased
matrix and increased cellularity, leading to an accentuated
lobular appearance of the glomerular tuft. Mesangial and
subendothelial immune deposits are observed with variable
degrees of cellular interposition into the capillary wall with
new basement synthesis giving rise to duplicated or split
glomerular basement membranes. MPGN can be idiopathic
or secondary to a variety of diseases. Systemic conditions
associated with MPGN include autoimmune diseases,
chronic infections (for example, hepatitis C), lymphoproli-
ferative disorders, and plasma cell dyscrasias.1–8
Several previous studies have evaluated MPGN recurrence
after kidney transplantation.9–12 All of these studies are
limited in part by low numbers of patients, the presence of
different disease subtypes, and also by the fact that the
diagnosis of recurrence was based on clinical grounds. Likely
owing to these reasons, the reported rate of recurrence of
MPGN is quite variable (27–65%) and the time of diagnosis
of recurrent MPGN (rMPGN) may not reflect the time of
initiation of the disease in the allograft. To address some of
these limitations, we used protocol biopsies in this study to
assess the incidence and risk factors for rMPGN. We
hypothesized that the use of these biopsies would allow us
to diagnose early disease, before it is clinically apparent, and
also to assess the clinical and histological evolution of MPGN
in allografts. In previous studies, we have used protocol
biopsies to assess the recurrence of other glomerular diseases
such as membranous nephropathy and fibrillary glomerulo-
pathy.13,14 We believe that those studies have provided
valuable insights into the mechanisms of early kidney
allograft injury.
One of the challenges of studying MPGN is its variable
etiology. We approached this issue by first selecting for study
all of the patients with classic histological findings for the
disease. In particular, patients with MPGN type II or with
fibrillary glomerulopathy were excluded from these analyses.
Second, we excluded patients with clear evidence of
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secondary MPGN, such as cryoglobulinemia. However, some
patients in this study had other diseases or abnormalities that
might have been associated with the development of MPGN.
RESULTS
Patient characteristics
Table 1 shows the characteristics of this patient cohort. Out
of these 29 recipients, 8 (27%) did not receive dialysis before
the transplant and 72% received kidneys from living donors.
Levels of the serum complement component C3 were
measured in 23 of 29 patients (79%) and C4 in 22 patients
(76%) in either pre- and/or post-transplant sera. C3 levels
were low in eight patients (8/23; 34.8%) and C4 levels were
low in eight patients (8/22; 36.4%). C3 and C4 were both low
in four patients. Serum cryoglobulins were measured pre-
and/or post-transplant in 18 of 29 patients (62%) and were
undetectable in all. Complete investigation for serum
monoclonal proteins (electrophoresis and immunofixation)
was performed before transplant in 26 of the 29 patients
(90%). Six of these patients (23.1%) had monoclonal
proteins in serum (three immunoglobulin (Ig)Gl, one IgGk,
and two with biclonal gammopathy composed of IgMk and
IgGl). One patient with serum monoclonal proteins had
chronic lymphocytic leukemia and four were diagnosed with
monoclonal gammopathy of unknown significance based on
bone marrow biopsies that were not consistent with multiple
myeloma. One patient did not undergo bone marrow biopsy.
One additional patient had no detectable monoclonal proteins
in serum before or after transplant, but his kidney biopsies
both before and after transplantation showed monotypic
deposition of IgMl in the glomerular mesangium.
In 22 of the 29 patients, there was no apparent cause for
the MPGN. However, in seven patients, there were other
clinical findings that could have been related to the MPGN,
including one patient with a history of rheumatoid arthritis;
one patient with idiopathic, serologically negative vasculitis;
one patient with chronic lymphocytic leukemia before the
transplant; and finally, two patients with hepatitis B and two
patients with hepatitis C based on PCR testing. One of the
patients with hepatitis had no evidence of serum cryoglobu-
lins and the remaining three were not tested. However, none
of the patients with hepatitis had evidence of cryoglobulins
on their native kidney biopsy. Of interest, none of the
patients with hepatitis developed rMPGN.
Recurrent MPGN: clinical presentation and evolution
During 52.8±36.9 months of follow-up (range 9–146
months), rMPGN was diagnosed in 12 of 29 patients
(41.4%). Figure 1 shows the cumulative incidence of
recurrent MPGN in this cohort of patients. As can be
observed, all recurrences occurred during the first 14 months
after transplant with a median time to recurrence of 3.3
months (range 1 week to 14 months). The diagnosis of
rMPGN was made by protocol biopsy in 6 of the 12 cases
(50% of all recurrences). In two additional patients, the
diagnosis was made in a clinical biopsy performed to evaluate
increasing creatinine in patients without proteinuria. Finally,
in four patients, the diagnosis of rMPGN was suspected on
the basis of the presence of proteinuria and confirmed in a
clinical biopsy.
The clinical presentation of rMPGN was quite variable
(Table 2). Four patients presented with features of glomerular
disease (patients 1–4, Table 2). An additional patient (patient
5) was initially diagnosed by biopsy when he had no
proteinuria, but within the next 4 months he developed
nephrotic range proteinuria. Among the four patients with a
clinical presentation, three had recurrent MPGN at 1–3
months after transplant, presenting with high-grade protei-
nuria and deterioration of kidney function. Of interest, one
of these patients (patient 3) had a history of rMPGN
resulting in early graft failure in three previous transplants.
The fourth patient with a clinical presentation (patient 4)
presented with high-grade proteinuria at 10 months after
transplantation and lost his allograft within 1 year of the
diagnosis of rMPGN. This patient had no evidence of
monotypic immunoglobulin deposits on allograft biopsy.
Patient 5 (Table 2) had a kidney biopsy performed within 1
week after transplant for evaluation of delayed graft function.
Table 1 | Patient characteristics
Variable All patients
Number of patients 29
Age 48.1±15.0
Sex (% males) 19/29 (65.5%)
Race (% Caucasians) 26/29 (89.7%)
Preemptive 8/29 (27.6%)
% Living donor 21/29 (72.4%)
Complement levels
Low C3 8/23 (34.8%)
Low C4 8/22 (36.4%)
Low C3 and/or C4 12/23 (52.2%)
Serum monoclonal proteins 6/26 (23.1%)
Follow-up (months) 52.8±36.9
Month of recurrence
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Figure 1 |Kaplan–Meier plot of the cumulative incidence of
recurrent membranoproliferative glomerulonephritis (MPGN)
after kidney transplantation.
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That biopsy was diagnosed as rMPGN, mainly on the basis of
immunofluorescence (IF) findings because the light micro-
scopy (LM) findings were minimal and atypical (see later).
This patient’s clinical and histological disease progressed
rapidly within the next 4 months, and he developed high-
grade proteinuria, new renal dysfunction, and classic
histological features of MPGN.
The four patients presenting with rMPGN early after
transplant (patients 1–3 and 5) were treated with plasma-
pheresis (PP). Three of these four patients responded to PP
with reduction in proteinuria and improvements in graft
function and blood pressure. However, two of these patients
remain on once-weekly PP at 12 and 13 months after the
transplant. The third patient (patient 2) responded partially
to PP but had progressive deterioration of graft function
requiring initiation of dialysis at 12 months after transplant.
This patient had a repeat bone marrow biopsy after
transplant that was diagnosed as smoldering multiple
myeloma and she subsequently received a stem cell
transplant. Surprisingly, her allograft function recovered after
the stem cell transplant and this patient has maintained stable
graft function for the past 5 years with a most recent
creatinine of 1.8mg/dl and an estimated glomerular filtration
rate of 31ml/min per 1.73m2. One additional patient
(patient 3) treated with PP had progressive deterioration of
function and lost the graft at 6 months after transplantation.
In this patient, a similar evolution had occurred in three
previous allografts resulting in early graft failure.
In 7 patients (patients 6–12, Table 2), the diagnosis of
rMPGN was made either by protocol biopsy or by a clinical
biopsy performed in a patient without proteinuria. At the
time of diagnosis, six of these seven patients had proteinuria
o250mg/day and one patient had proteinuria 420mg/day.
At 1 year after the histological diagnosis of rMPGN,
proteinuria increased significantly in four patients and
declined in two (Table 2).
During follow-up, 5 of 29 grafts were lost (17%, death
censored). The proportion of grafts lost was not significantly
different among patients with rMPGN (2/12, 17%, cause of
graft failure, recurrent disease) and in those without
recurrence (3/15, 20%; chi-square: P¼ 0.629; Kaplan–Meier
log rank P¼ 0.895).
Variables associated with recurrent MPGN
Table 3 compares the characteristics of patients with or
without rMPGN. There were no significant differences in the
demographic characteristics of these two groups of patients.
None of the patients with hepatitis B or C had recurrent
disease. Two patients, one with rheumatoid arthritis and one
with idiopathic, serologically negative vasculitis, had rMPGN.
Table 2 | Clinical presentation of recurrent MPGN
Presentation Follow-up
Patient Diagnosis month (mode) SCr/UProt/M proteina SCr/UProt (B1 year after diagnosis) Treatment/outcome
1 0.8 (C) 1.8/3508/M 1.7/1784 PP/BMT
2 1.5 (C) 1.8/3272/M 3.3/3562 PP/BMT
3 2 (C) 1.9/13019/M Dialysis PP/allograft lost
4 10 (C) 2.2/9020/no M 9.8/17,625 Allograft lost
5 0.3 (SC/C)b 4.5/o250/no M 3.7/7676 PP/rituximab
6 3 (SC) 1.9/420/no M 1.6/1555 Rituximab
7 3 (SC) 1.6/219/no M 1.5/63 Rituximabc
8 4 (SC) 1.7/197/NA 1.7/681 None
9 4 (SC) 1.2/61/no M 2.1/162 None
10 5 (SC) 4.2/117/no M 1.5/83 Rituximab
11 5 (SC) 2.3/89/M 2.6/263 None
12 14 (SC) 1.4/245/no M Short follow-up None
Abbreviations: BMT, bone marrow transplant for smoldering multiple myeloma; C, clinical; MPGN, membranoproliferative glomerulonephritis; NA, not available;
PP, plasmapheresis; UProt, urine protein at diagnosis.
aSerum creatinine at diagnosis/urine protein at diagnosis (mg24 h)/M=serum monoclonal protein present.
bHistological recurrence in 1 week post-transplant biopsy for evaluation of delayed graft function with increasing levels of proteinuria over the ensuing 4 months (both
biopsies stained for IgMl in glomeruli but had no demonstrable serum monoclonal protein).
cPatient received rituximab primarily in an attempt to reduce her anti-HLA class II antibodies.
Table 3 | Comparison between patients with and without
recurrent MPGN
Variable Recurrent Nonrecurrent P-value
Number of patients 12 17
Age 49.4±15.4 47.2±15.9 NDa
Sex (% males) 66.7% 64.7% NDb
Race (% Caucasians) 100% 82.4% NDb
Preemptive 30% 23.5% NDb
% Living donor 91.7% 58.8% 0.051b
Immunosuppression
Thymoglobulin (%) 83.3% 52.9% NDb
Tacrolimus (%) 100% 82% NDb
Complement levels
Low C3 41.7% 27.3% 0.469b
Low C4 50% 20% 0.145b
Low C3 and/or C4 75% 27.3% 0.022b
Monoclonal proteins (serum) 4/11 (36%) 2/15 (13%) 0.169b
Follow-up (months) 40.6±27.5 61.5±40.9 NDa
Abbreviations: MPGN, membranoproliferative glomerulonephritis; ND, not different.
aStudent’s t-test.
bChi-square test.
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Recurrence seemed to be more common in recipients of
living donors. Thus, among the 12 patients with rMPGN, 11
(91%) were recipients of living donor kidneys, whereas
among the 17 patients without a recurrence, 10 (59%) were
recipients of living donor kidneys. This numerical difference
did not reach statistical significance (P¼ 0.051 by chi-square;
Figure 2a). Recurrence was significantly more common in
patients with low serum complement levels (either C3 or C4
or both; hazard ratio 4.340, confidence interval 1.139–16.541,
P¼ 0.03; Table 3 and Figure 2b). Compared with patients
without monoclonal proteins, there were trends suggesting
that the presence of serum monoclonal proteins was
associated with an increased incidence of rMPGN (Table 3
and Figure 2c) that more often had a clinical presentation (29
vs 75%, P¼ 0.137). However, these apparent differences did
not reach statistical significance. Interestingly, one patient
with monotypic IgMl deposition in glomeruli (patient 5;
Table 2) also had a very rapid recurrence and responded to
PP, although he continues to require once-weekly PP to
maintain stable kidney function and lower levels of
proteinuria. Despite many attempts, this patient has had no
demonstrable monoclonal proteins in the serum and his
bone marrow biopsy was not indicative of a plasma cell
dyscrasia.
Previous studies showed an association between the
human leukocyte antigen phenotype B8 DR3 and recurrent
disease.9,10 However, in this cohort of patients, the propor-
tion of patients with this human leukocyte antigen
phenotype was not significantly different between recipients
with recurrence (20%) and those without recurrence (19%;
P¼ 0.937).
Histology of rMPGN
The median number of biopsies per patient after transplanta-
tion was 4 (range 1–7). Out of 12 patients, 9 with rMPGN
had follow-up biopsies after the diagnostic biopsy. Selective
findings on the diagnostic and follow-up biopsies of patients
with rMPGN are shown in Table 4.
The severity of the histological changes of rMPGN
paralleled the severity of the clinical presentation and
evolution. Patients with a clinical presentation had char-
acteristic light microscopic features of MPGN, including
endocapillary and mesangial proliferation and duplication of
glomerular basement membranes. In addition, subendothe-
lial and mesangial electron-dense deposits were present on
electron microscopy (EM). In contrast, patients with a
subclinical presentation had milder or minimal histological
changes, but those changes progressed over time.
The four patients presenting clinically (patients 1–4 in
Tables 2 and 4) had advanced MPGN changes in the
diagnostic biopsy, despite the fact that in three of these
patients the diagnosis was made within the first 3 months
after transplant. Furthermore, these histological changes
progressed rapidly and paralleled changes in the clinical
manifestations, including marked deterioration of graft
function and high-level proteinuria (see Table 2). Three of
these four patients (patients 1–3) had serum monoclonal
proteins. However, by IF there was no light chain restriction
on the biopsy. The final patient with a clinical presentation at
10 months after transplant (patient 4) also had advanced
histological features at diagnosis (no previous biopsy
available on this patient) and rapidly lost the allograft. This
patient did not have a demonstrable M protein in the serum
and his allograft biopsy was not suggestive of monotypic
immunoglobulin deposits. Patient 5 (Tables 2 and 4) was
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Months post-transplant
24120
Months post-transplant
24120
Months post-transplant
24120
Pr
op
or
tio
n 
of
 p
at
ie
nt
s 
wi
th
rM
PG
N
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Pr
op
or
tio
n 
of
 p
at
ie
nt
s 
wi
th
rM
PG
N
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Pr
op
or
tio
n 
of
 p
at
ie
nt
s 
wi
th
rM
PG
N
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Complement levels and rMPGN
Serum monoclonal proteins and rMPGN
a
b
c
Figure 2 | Incidence of recurrent membranoproliferative
glomerulonephritis (rMPGN). (a) Incidence of rMPGN in
recipients of living donor kidneys (—) and in recipients of
deceased donor kidneys (–––) (P¼ 0.063 log rank). (b) Incidence of
rMPGN in patients with low complement levels (–––) and in
patients with normal complement levels (—) (P¼ 0.020, log rank).
(c) Incidence of rMPGN in patients with serum monoclonal
proteins (–––) and in patients without these proteins (—)
(P¼ 0.083, log rank).
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initially diagnosed when he had no significant proteinuria.
The LM on this biopsy showed minimal changes, but he had
positive IF and mesangial but no subendothelial deposits by
EM (Figure 3). At 4 months after the initial diagnosis, repeat
biopsy showed typical microscopic changes of MPGN
(Figure 3). Both allograft biopsies showed monotypic
deposits of IgMl, and by EM the deposits had no fibrillary
structure. Interestingly this patient had the same IF pattern in
his native kidney biopsy (mesangial IgMl).
In eight patients with a subclinical presentation, the initial
biopsy findings were mild, including mesangial expansion
and mesangial dense deposits but rare or absent subendothe-
lial deposits and no duplication of glomerular basement
membranes. In fact, five of these eight patients had no light
microscopic features of MPGN. However, immunofluores-
cence deposition of immunoglobulins and/or C3 was present
in all cases and, together with the history of MPGN,
suggested the diagnosis of recurrence. It should be noted
that the histological changes progressed in five of these eight
patients. Thus, on follow-up biopsies, the characteristic light
microscopic changes of MPGN with basement membrane
double contouring became apparent in all cases and the
percentage of glomeruli showing these changes increased
rather dramatically in three cases (patients 6, 7, and 11 in
Table 4). Of interest, this histological progression was
associated with changes in the clinical picture that would
generally be considered minor (note patient 11).
DISCUSSION
These analyses extend previous observations on the outcomes
of kidney transplantation in patients with MPGN. In this
study, we first selected patients on the basis of the
characteristic histological features of MPGN, eliminating
those patients with fibrillary glomerulopathies or MPGN
type II. MPGN is the pathologic end result of multiple
etiologies. However, the etiologic link between a particular
disease and MPGN is often uncertain. Thus, among the
patients included in this study, there were a minority with
other diseases that might have caused the MPGN, such as
Table 4 | Biopsy findings in 12 patients with recurrent MPGN
Light microscopy Immunofluorescence Electron microscopy
Patient Biopsy monthsa MMb
% Affected
glomerulic IgGd C3 j k
Mesangial
deposits
Subendo.
deposits
GBM
duplicat.
1 0.8/3 3/3 64/100 1mc/1c 2mc/1c 0/0 0/0 2/1 1/1 tr/1
2 1.5/33 3/2 78/100 0/0 1c/2mc 0/0 0/0 1/1 1/2 tr/2
3 2 2 25 0 3m 0 0 2 2 2
4 10/12 3/2 88/100 3mc/3mc 3mc/3mc 3mc/2mc 3mc/3mc 2/2 1/1 1/1
5 0.3/4 2/3 0/100 0/0 (3/3 IgM) 3mc/3c 0/0 3mc/3c 2/1 tr/2 tr/tr
6 3/24 2/3 12/33 0/0 trc/1c 1c/1c 1c/1c 2/1 1/1 tr/1
7 3/6 1/1 0/22 1c/0 0/3m 1c/0 1c/0 1/2 0/1 1/2
8 4 1 25 0 3m 0 0 3 1 1
9 3/34 NT/2 NT/6 2m/2m 2m/2m 2m/2m 1m/trm 2/2 tr/1 0/1
10 5/5 2/1 71/15 3mc/3mc 3mc/3mc 0/0 3mc/3mc 1/0 3/3 2/2
11 5/10 2/2 0/88 2m/2m 3m/3mc 2m/2mc 2m/trc 3/2 1/1 tr/1
12 14 2 0 0 trm 0 1m 1 1 2
Abbreviations: c, capillary wall; duplicat., duplication; GBM, glomerular basement membrane; IgG, immunoglobulin G; m, mesangium; MM, mesangial matrix expansion;
MPGN, membranoproliferative glomerulonephritis; subendo., subendothelial; tr, trace; v, vascular.
aMonths after transplant: diagnostic biopsy/last biopsy.
bSemiquantitative score of mesangial expansion (1–3+).
cPercentage of glomeruli with MPGN changes.
dImmunofluorescence data expressed as semiquantitative score (1–3+) and by location.
Figure 3 |Histological evolution of recurrent
membranoproliferative glomerulonephritis (MPGN) in patient 5.
(a) Light microscopy at 1 week after transplant showing mild
mesangial expansion (arrow) with increase in matrix and
cellularity owing to increased mononuclear cells (silver stain,
original magnification  60); (b) electron microscopy at 1 week
after transplant showing mesangial deposits (arrow; original
magnification  7400); (c) light microscopy at 4 months after
transplant showing mesangial expansion with increase in matrix
and cellularity owing to increased mononuclear cells,
endocapillary proliferation, and thickened capillary walls with
double contouring (arrow) resulting in an MPGN pattern (silver
stain, original magnification  60); (d) electron microscopy at
4 months after transplant showing extensive capillary wall deposits
with double contouring (arrow; original magnification  4200).
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rheumatoid arthritis. In addition, there were four patients
with serologic evidence of hepatitis B or C. However, none of
these patients had evidence of cryoglobulins and, interest-
ingly, none of these patients had recurrent disease.
In this study we showed that a high proportion of patients
with MPGN have serum monoclonal proteins (23%). In the
general population, serum monoclonal proteins are found in
only 3.2% of adults older than 50 years and in 5.3% of adults
older than 70 years.15 The results of this study are consistent
with our initial observations that patients with MPGN and
serum monoclonal proteins seem to have a higher incidence
of early, more clinically aggressive recurrence. However, these
data should be interpreted with caution because the number
of patients with rMPGN and monoclonal proteins in this
study was small. Furthermore, the serum monoclonal
proteins were not demonstrable in the glomerular deposits.
Despite this fact, these clinical observations are consistent
with the hypothesis that serum monoclonal proteins were
involved in the pathogenesis of the MPGN. This indirect
evidence includes the clinical response of rMPGN to
plasmapheresis and the resolution of recurrence in one
patient after bone marrow transplantation. Perhaps related to
these observations, previous studies showed the capacity of
some monoclonal proteins to activate the alternative pathway
of the complement cascade resulting in MPGN.16 Interest-
ingly, four of the five patients (80%) in this study who had
monoclonal proteins and underwent complement testing had
low C3 and/or C4 levels. Consistent with this observation, we
recently showed that patients with fibrillary glomerulone-
phritis and serum monoclonal proteins have a high incidence
of recurrence.13 The association described in this study
between monoclonal proteins and MPGN should be
differentiated from the observation that some patients with
MPGN have monotypic immunoglobulin deposits in the
glomeruli. Interestingly, only 30% of these latter patients
have demonstrable serum monoclonal proteins.17
In this cohort of patients, 41% had rMPGN and the
recurrence was demonstrable early, at a median of 3.3 months
after transplant. In previous studies, the reported incidence
of rMPGN has varied from 27 to 65%. This variability is
likely because of different patient selection criteria and the
reliance on clinical parameters to diagnose rMGPN.9–12 The
use of protocol biopsies allowed us to make an earlier
histological diagnosis and also to show that the relationship
between histology and clinical manifestations of MPGN is
quite variable. Thus, all of the patients with early, clinically
apparent recurrence had advanced histological lesions that
progressed rapidly. In contrast, patients with subclinical
rMPGN initially had milder histological features. Interest-
ingly, the clinical manifestations frequently remained mild
despite clear histological progression of the glomerular
lesions. These observations once again remind us that MPGN
likely represents a group of diseases with different rates of
progression and likely different etiologies.
The results of these analyses showed an association
between low serum complement levels and recurrence. Thus,
patients with low C3 and/or low C4 had a fourfold higher
recurrence rate when compared with patients with normal
complement levels. This result is consistent with some
previous studies18 but not others.19 Low complement levels
in MGPN can be due to the presence of nephritic factors,
either C3 or C4,20,21 and the presence of these autoantibodies
may be related to the risk of recurrence. Unfortunately, none
of our patients was tested for the presence of nephritic
factors. Furthermore, recent studies have shown an associa-
tion between defective alternative pathway complement
activation and MPGN, although most involve histology
consistent with MPGN type II.22 However, patient selection
in these previous studies is not entirely clear. This study also
suggests that transplantation with a living donor kidney may
be associated with a higher risk of rMPGN. Although this
association did not reach statistical significance, likely owing
to low patient number, this association is worth considering
in the clinic. A previous study also suggested a higher
likelihood of rMPGN in recipients of living donor kidneys.9
Previous studies from our group emphasized the effect of
recurrent glomerular disease on kidney allograft survival.23 In
particular, 17% of patients with MPGN lost their allograft
because of recurrent disease. Previous studies showed a
comparable incidence of graft loss of 14.4%.24 In this cohort
of patients, there were only five death-censored graft losses;
thus, this study is not sufficiently powered to compare graft
survival in patients with MPGN, with or without rMPGN.
The hypothesis guiding these studies is that early diagnosis of
recurrence by protocol biopsies may provide information
regarding disease pathogenesis as well as an opportunity for
more effective treatment. The findings of this study and a
previous study on membranous nephropathy14 support the
validity of this postulate. The atypical histology of early
rMPGN suggests that the pathologic criteria currently used to
make this diagnosis apply only to advanced disease. Thus, in
its earliest phases, MPGN is not associated with basement
membrane duplication or subendothelial deposits, but rather
is a mesangial glomerulonephritis generally with strong C3
staining but scant immunoglobulin deposition. The postulate
that earlier diagnosis may lead to more effective therapy
unfortunately remains untested. Patients with monoclonal
proteins and acute recurrence seem to benefit from
plasmapheresis, and we believe that this treatment should
be tested under these clinical circumstances. In the absence of
monoclonal proteins, disease recurrence is clinically milder.
However, the future of grafts with rMPGN is of concern
because repeat biopsies showed histological progression of
the disease.
These studies suggest that when contemplating kidney
transplantation in a patient with MPGN, determinations of
serum complement levels and a search for monoclonal
proteins by immunofixation may help in better defining the
risk of recurrence. In patients with monoclonal proteins, we
believe it is worthwhile to investigate their bone marrow to
assess whether or not they have a plasma cell dyscrasia. In
these patients, recurrence can occur very early after
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transplant and can be very acute, and therefore careful
surveillance is important, including the frequent monitoring
of proteinuria. In our experience, patients with early,
aggressive rMPGN frequently have serum monoclonal
proteins and are generally responsive to plasmapheresis.25
This treatment was effective in three of the four patients
described in this study, but was palliative not curative.
MATERIALS AND METHODS
Patient population
The Mayo Clinic Transplant database was queried for all patients
with MPGN who underwent kidney transplantation between 1996
and 2006. During that time, 1321 patients underwent transplanta-
tion and 36 (3%) had MGPN. The pre-transplant diagnosis of
MPGN was confirmed by a review of native biopsies when they were
performed at our institution or by a review of pathology slides or
reports when the biopsies were performed elsewhere (N¼ 18).
Patients with MPGN type II and those with fibrillary glomerulone-
phritis were excluded from this study, considering that these diseases
are histologically and pathogenically distinct from MPGN. The
primary aim of this study was to assess the rate of histological
recurrence of MPGN. Thus, 7 of the 36 patients were excluded from
the analysis because they had no post-transplant biopsies. None of
these seven patients had clinical evidence of recurrent MPGN or
abnormal proteinuria. Demographic, clinical, and histological
information regarding transplantation, treatment, and follow-up
were extracted from the Mayo Clinic electronic records. The search
for these data and the publication of this study were approved by the
institutional review board of the Mayo Foundation.
The immunosuppression protocols used in the 29 patients included
in this study included induction immunosuppression with thymo-
globulin (N¼ 19, 65.5%), anti-CD25 antibodies (N¼ 7, 24.1%), OKT3
(muromonab-CD3) (N¼ 1, 3.4%), or none (N¼ 2, 6.9%). Maintenance
immunosuppression consisted of corticosteroids (tapering to 5mg daily
after the third month after transplant), mycophenolate mofetil (750mg
twice daily), and either tacrolimus in 26 patients (89.7%), sirolimus in
2 patients (6.9%), or cyclosporine in 1 patient (3.4%).
In our transplant program, protocol allograft biopsies are
performed at the time of transplantation (time 0) and at 4, 12,
24, and 60 months after transplant.26 These biopsies are not dictated
by clinical indications. Two of the researchers (ECL and FGC)
reviewed all post-transplant allograft biopsy reports from protocol
or clinical biopsies. Furthermore, the LM slides, IF report, and EM
photographs from all of the biopsies with evidence of MPGN were
reviewed by two researchers (ECL and SS). The diagnosis of rMPGN
was based on LM and/or IF and/or EM findings. It should be noted
that on follow–up, all of the biopsies had characteristic changes of
MPGN by light microscopy. However, on early diagnostic biopsies,
LM changes were often minimal or not apparent. The determination
of non-recurrence was based on lack of histological findings by LM,
IF, and EM.
In addition to the routine post-transplant laboratory tests,14 all
individuals transplanted at our institution had serum monoclonal
protein studies (immunoelectrophoresis) performed at the time of
transplantation. In addition, immunofixation was performed on
stored frozen serum from patients in whom these studies were not
available. The search for monoclonal proteins in patients with
MPGN is justifiable by previous studies showing this association.17
Serum complement levels were analyzed and considered as normal
or lower than the reference range for our laboratory (reference
ranges: C3 75–175mg/dl, C4 14–40mg/dl). None of these patients
was tested for the presence of nephritic factors.
Data analysis
Data are expressed as means with s.d. Proportions were compared
using chi-square test. Numerical data were compared using
Student’s t-test if normally distributed, and nonparametric tests if
not normally distributed. MPGN recurrence over time was assessed
using Kaplan–Meier plots. The associations between recurrence and
other variables were assessed using Cox regression analysis.
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